Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15d42f684941d5b0617ca7764ebdff07 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-582 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate |
2010-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a6d67230d113b367e2b29b78e8ff144 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8cf0b2b8c151e53be585482ad017fab |
publicationDate |
2010-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2010331390-A1 |
titleOfInvention |
Effects of apolipoprotein b inhibition on gene expression profiles in animals |
abstract |
Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10557137-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10883104-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109735541-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014179620-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014179625-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4119569-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9347061-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11299736-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017079745-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400161-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10570169-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9181550-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9163239-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9127276-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9181549-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10875884-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9932581-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9617331-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8916694-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013076730-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9382540-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9957504-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017079739-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9957292-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11319536-B2 |
priorityDate |
2002-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |